



The Product Realization Company

FOR IMMEDIATE RELEASE

PLEXUS RECEIVES MEDICAL CERTIFICATION IN CALIFORNIA FACILITY

NEENAH, WI, November 13, 2012 -- Plexus Corp. (NASDAQ: PLXS), announced today that it has received ISO 13485 certification at its San Jose, CA facility. ISO 13485 is an international standard containing requirements for establishing and maintaining quality management systems for medical devices. The certification reinforces Plexus' previously established compliance with the unique quality, regulatory and technology requirements of the industry, and reaffirms its dedication to serve its customers in this critical market.

Mike Tendick, Market Sector Vice President for Plexus' Healthcare/Life Sciences Market Sector, commented, "We proactively align our quality and regulatory activities to meet our customers' needs. Achieving ISO 13485 certification in our San Jose facility highlights our commitment to providing Product Realization services to our West Coast Healthcare/Life Sciences customers in this important technology region."

"We are proud of this accomplishment. In this competitive environment, Plexus offers our customers assurance that our facility embraces the most stringent quality and regulatory requirements of the medical device industry." said Don Landry, General Manager of Plexus Manufacturing Solutions San Jose. "Plexus provides our customers with the competitive advantage they require. We deliver optimized solutions, customer service excellence and flawless execution."

This certification was awarded, after extensive third-party audits, by DNV Certification, one of the world's leading certification bodies. It covers a variety of our industry leading Product Realization Value Stream solutions including commercialization, manufacturing, fulfillment and sustaining solutions.

For further information, please contact:

Mike Tendick, Healthcare/Life Sciences Market Sector Vice President – Plexus Corp.
920-751-3614 or michael.tendick@plexus.com

About Plexus Corp. – The Product Realization Company

Plexus (www.plexus.com) delivers optimized Product Realization solutions through a unique Product Realization Value Stream service model. This customer-focused services model seamlessly integrates innovative product conceptualization, design, commercialization, manufacturing, fulfillment and sustaining services to deliver comprehensive end-to-end solutions for customers in the America, European and Asia-Pacific regions.

Plexus is the industry leader in servicing mid-to-low volume, higher complexity customer programs characterized by unique flexibility, technology, quality and regulatory requirements. Award-winning customer service is provided to over 130 branded product companies in the Networking/Communications, Healthcare/Life Sciences, Industrial/Commercial and Defense/Security/Aerospace market sectors.

Safe Harbor and Fair Disclosure Statement

The statements contained in this release which are guidance or which are not historical facts (such as statements in the future tense and statements including “believe,” “expect,” “intend,” “plan,” “anticipate,” “goal,” “target” and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the timing and effect on Plexus’ net sales, margins and results of operations of Juniper’s intended disengagement. They also include but are not limited to: the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the poor visibility of future orders, particularly in view of current economic conditions; the economic performance of the industries, sectors and customers we serve; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; the risk that our agreement with Kontron does not result in the revenues or margins anticipated by us; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the particular risks relative to new or recent customers or programs, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the risks of concentration of work for certain customers; our ability to manage successfully a complex business model characterized by high customer and product mix, low volumes and demanding quality, regulatory, and other requirements; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; the effects of shortages and delays in obtaining components as a result of economic cycles or natural disasters; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; the weakness of areas of the global economy and the continuing instability of the global financial markets and banking system, including the potential inability of our customers or suppliers to access credit facilities; the effect of changes in the pricing and margins of products; the effect of start-up costs of new programs and facilities, such as our announced plans to replace facilities in Romania and the United States, and other recent, planned and potential future expansions; increasing regulatory and compliance requirements; possible unexpected costs and operating disruption in transitioning programs; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the potential effect of world or local events or other events outside our control (such as drug cartel-related violence in Mexico, changes in oil prices, terrorism and weather events); the impact of increased competition; and other risks detailed in the Company’s Securities and Exchange Commission filings (particularly in Part I, Item 1A of our annual report on Form 10-K for the fiscal year ended October 1, 2011). In addition, we cannot provide assurances as to whether or when any repurchases under our share repurchase program will be made.

###